Current and developing therapeutic agents in the treatment of Chagas disease
about
Chagas disease: "the new HIV/AIDS of the Americas"Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical diseaseTranslational challenges of animal models in Chagas disease drug development: a reviewTrypanocidal activity of marine natural productsEndothelial transmigration by Trypanosoma cruziRational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas AgentsDevelopment of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas DiseasePhenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of Trypanosoma cruzi infection.The investigation of congenital infection by Trypanosoma cruzi in an endemic area of Chile: three protocols explored in a pilot project.Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.Clinical aspects of Chagas disease and implications for novel therapies.Mother-to-Child Transmission of Chagas Disease in El Salvador.The Trypanosoma cruzi Diamine Transporter Is Essential for Robust Infection of Mammalian Cells.Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studiesSynthesis and Evaluation of Oxyguanidine Analogues of the Cysteine Protease Inhibitor WRR-483 against Cruzain.Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.The absence of myocardial calcium-independent phospholipase A2γ results in impaired prostaglandin E2 production and decreased survival in mice with acute Trypanosoma cruzi infection.Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods.Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospectsReversible cysteine protease inhibitors show promise for a Chagas disease cure.Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence.cAMP signalling in trypanosomatids: role in pathogenesis and as a drug target.Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment In Vivo Assay.Computer-Aided Drug Design Using Sesquiterpene Lactones as Sources of New Structures with Potential Activity against Infectious Neglected Diseases.Pediatric enteric neuropathies: diagnosis and current management.Structural insights of SIR2rp3 proteins as promising biotargets to fight against Chagas disease and leishmaniasis.Structure-dependent binding of arylimidamides to the DNA minor groove.Experimental and Clinical Treatment of Chagas Disease: A Review.Congenital infection by Trypanosoma cruzi in an endemic area of Chile: a multidisciplinary study.Trypanosome prereplication machinery: a potential new target for an old problem.Benznidazole modulates cell proliferation in acute leukemia cells.
P2860
Q21144502-118DFF50-A9E3-4415-AE62-F7082DE538E2Q24597322-E1CF2AE2-9921-4FD0-B95D-07FE70AD0FB3Q26796451-56380326-2CFA-4BD6-BFBD-E1CA06EE93F6Q27008593-A88018A7-ACF0-457C-82C4-42A24D3EACDBQ27301348-22902ACF-E660-456E-AF35-8C445030137EQ27680103-A3DEEABD-70F3-404D-AB14-8397AC6CE29FQ28548320-1F74D6FE-F0EF-484E-BCAB-899264A4974CQ33553551-88AA934F-A3B3-4E61-9283-3B7338619099Q33854932-74115BC6-C585-4A56-ADCB-14EDDB19081BQ35189546-969F95C6-D748-40EF-AEA6-BEFBEAEA0197Q35367533-F41BD27A-8CA5-4947-B2D4-C2C35637F3ECQ35676177-E9D1B04E-C73D-452C-9837-37C52E223E24Q35933969-EEC4EE85-BBBC-45B6-8583-B44B9A28B00BQ35981043-D0BB5341-DC0B-4782-99DB-2E4C02C9FD4EQ36086468-F8BB97CC-14B1-4007-8ECB-A1FF6A3791E1Q36473159-0E365BD6-8406-4B8A-8946-1C55CCFE019CQ36571788-95ACF180-5CAC-48F7-A9C2-9444AB5F788BQ36970825-8DA04BBA-BABA-4492-BD9C-9A28FA3076AFQ37124216-44937BD4-EDD4-48A4-8017-F0FE5CD51D2CQ37286061-EB4FEBA0-F9DF-4B7C-B129-CBC6939748D4Q37544765-FF9179B8-439B-41C6-B526-5B27E48E0706Q38017721-DE7819EA-D416-4A99-A058-57EBC85E16CCQ38500595-205FB187-EE5D-42F5-A31B-0BE7EA3FBE26Q38938717-2D1EB546-04AF-4DEF-BBAB-7A461EA21AADQ39065488-D72399E6-CE69-4F77-BD5E-312C8C7BE9F4Q39188089-A1FCA52E-31B8-4747-B67C-F0B66A500F48Q39396789-07C644C6-CCD6-4926-924F-6CA328290AD9Q41910359-A2B7E6B5-FF6E-44F2-A275-16DAF0BD6A42Q41989175-27549186-1F28-4351-93E5-872C87814113Q42283353-2E43B51A-148A-45FC-9E10-6884B9A7CA6FQ42752722-726F7235-9CB2-4B5E-ADDE-F3D6C51398E8Q45071683-612BD36D-E3FE-47E3-B481-DE2BE16932A0
P2860
Current and developing therapeutic agents in the treatment of Chagas disease
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Current and developing therapeutic agents in the treatment of Chagas disease
@ast
Current and developing therapeutic agents in the treatment of Chagas disease
@en
Current and developing therapeutic agents in the treatment of Chagas disease
@nl
type
label
Current and developing therapeutic agents in the treatment of Chagas disease
@ast
Current and developing therapeutic agents in the treatment of Chagas disease
@en
Current and developing therapeutic agents in the treatment of Chagas disease
@nl
prefLabel
Current and developing therapeutic agents in the treatment of Chagas disease
@ast
Current and developing therapeutic agents in the treatment of Chagas disease
@en
Current and developing therapeutic agents in the treatment of Chagas disease
@nl
P2860
P356
P1476
Current and developing therapeutic agents in the treatment of Chagas disease
@en
P2093
Werner Apt
P2860
P304
P356
10.2147/DDDT.S8338
P407
P577
2010-09-24T00:00:00Z